Oric Pharmaceuticals Inc. 宣布,公司将进一步评估其候选药物Rinzimetostat在更多适应症中的应用潜力,重点聚焦于前列腺癌领域,并探索其在其他疾病治疗中的可能性。
Oric Pharmaceuticals Inc. 宣布,公司将进一步评估其候选药物Rinzimetostat在更多适应症中的应用潜力,重点聚焦于前列腺癌领域,并探索其在其他疾病治疗中的可能性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.